The Caisse de dépôt et placement du Québec (CDPQ) and Archimed Diagnostics have jointly acquired Stago, a French diagnostics company specializing in hemostasis testing. The deal, announced on April 29, 2026, marks a significant expansion for the Quebec-based institutional investor and its healthcare-focused partner into the European diagnostics market.
Strategic Acquisition in Healthcare
Stago, headquartered in Asnières-sur-Seine, France, is a global leader in hemostasis diagnostics, offering a range of products for blood coagulation testing. The company employs over 2,000 people worldwide and operates in more than 30 countries. The acquisition aligns with CDPQ's strategy to invest in high-growth healthcare sectors, particularly in diagnostics and medical technology.
Archimed Diagnostics, a private equity firm specializing in healthcare investments, will work alongside CDPQ to support Stago's growth initiatives. The partnership aims to leverage Stago's strong market position and innovative product pipeline to expand its global footprint.
Financial Details Not Disclosed
The financial terms of the transaction were not disclosed. However, industry analysts estimate the deal to be worth several billion euros, given Stago's estimated annual revenue of around €1.5 billion. The acquisition is subject to regulatory approvals and is expected to close in the coming months.
CDPQ has been increasingly active in healthcare investments, with a portfolio that includes stakes in pharmaceutical companies, medical device manufacturers, and healthcare services. This acquisition underscores the pension fund's commitment to diversifying its assets and generating long-term returns for its depositors.
Impact on Stago's Operations
Stago's management team will remain in place, and the company will continue to operate under its existing brand. The new owners have indicated that they plan to invest in research and development to accelerate innovation in hemostasis testing, as well as explore opportunities for expansion into adjacent diagnostic areas.
Stago's customers and employees are expected to benefit from the financial backing and strategic guidance of CDPQ and Archimed. The deal is seen as a positive development for the French diagnostics industry, which has been consolidating in recent years.
